


## Participant flow



## Baseline characteristics

| Demographic data                          | Enrolled/Safety set<br>N=12 | Pharmacokinetic set<br>N=11 |
|-------------------------------------------|-----------------------------|-----------------------------|
| <b>Age (years)</b>                        |                             |                             |
| Mean ± SD                                 | 46.9±11.2                   | 48.7±9.7                    |
| Median (range)                            | 49.0 (24-59)                | 49.0 (24-59)                |
| <b>Body weight (kg)</b>                   |                             |                             |
| Mean ± SD                                 | 64.94±8.42                  | 65.75±8.32                  |
| Median (range)                            | 65.10 (51.1-80.4)           | 67.40 (51.1-80.4)           |
| <b>Height (cm)</b>                        |                             |                             |
| Mean ± SD                                 | 162.4±5.8                   | 163.1±5.5                   |
| Median (range)                            | 164.0 (153-172)             | 164.0 (153-172)             |
| <b>Body Mass Index (kg/m<sup>2</sup>)</b> |                             |                             |
| Mean ± SD                                 | 24.67±3.31                  | 24.79±3.44                  |
| Median (range)                            | 23.80 (20.7-29.9)           | 24.30 (20.7-29.9)           |
| <b>Iron baseline value (µg/dL)</b>        |                             |                             |
| Mean ± SD                                 | -                           | 58.92±22.99                 |
| Median (range)                            | -                           | 65.35 (25.65-92.15)         |

## Outcome measures

### Primary outcome

Mean  $\pm$  SD iron concentrations after single (Day 1) and multiple (Day 3) doses of the investigational product are shown in the table below (N=11):

| Time                  | Day 1 (single dose) | Day 3 (multiple dose) |
|-----------------------|---------------------|-----------------------|
| <b>-12 h pre-dose</b> | 53.15 $\pm$ 21.25   | -                     |
| <b>Pre-dose</b>       | 64.68 $\pm$ 26.47   | 56.85 $\pm$ 21.15     |
| <b>1 h</b>            | 74.64 $\pm$ 27.49   | 69.21 $\pm$ 23.47     |
| <b>2 h</b>            | 91.53 $\pm$ 33.32   | 83.11 $\pm$ 27.96     |
| <b>3 h</b>            | 107.67 $\pm$ 47.10  | 91.03 $\pm$ 32.92     |
| <b>4 h</b>            | 110.94 $\pm$ 50.74  | 94.65 $\pm$ 36.13     |
| <b>5 h</b>            | 111.94 $\pm$ 50.97  | 95.74 $\pm$ 34.90     |
| <b>8 h</b>            | 99.49 $\pm$ 46.74   | 88.07 $\pm$ 31.69     |

As shown by the concentrations above, at Day 1 (i.e., following a single administration) mean iron concentrations were approximately doubled relative to baseline at around 5 h post-dose.

Mean  $\pm$  SD baseline-corrected iron concentrations after single (Day 1) and multiple (Day 3) doses of the investigational product are shown in the table below (N=11):

| Time            | Day 1 (single dose) | Day 3 (multiple dose) |
|-----------------|---------------------|-----------------------|
| <b>Pre-dose</b> | 58.92 $\pm$ 22.99*  | 6.97 $\pm$ 10.31      |
| <b>1 h</b>      | 15.72 $\pm$ 9.11    | 13.26 $\pm$ 17.93     |
| <b>2 h</b>      | 32.61 $\pm$ 16.24   | 24.19 $\pm$ 21.12     |
| <b>3 h</b>      | 48.75 $\pm$ 34.25   | 32.16 $\pm$ 25.67     |
| <b>4 h</b>      | 52.02 $\pm$ 37.93   | 36.13 $\pm$ 29.57     |
| <b>5 h</b>      | 53.02 $\pm$ 38.26   | 37.12 $\pm$ 28.51     |
| <b>8 h</b>      | 40.57 $\pm$ 36.97   | 30.09 $\pm$ 20.77     |

\*: baseline value calculated as the arithmetic mean of the serum iron concentrations measured at -12 h pre-dose on Day -1 and at pre-dose on Day 1

Descriptive statistics of iron pharmacokinetic parameters are presented in the table below:

| Pharmacokinetic parameters         | Day 1<br>Single dose | Day 3<br>Multiple dose |
|------------------------------------|----------------------|------------------------|
| <b>C<sub>max</sub></b> (µg/dL)     | 114.364±50.204       | 98.836±33.755          |
| <b>AUC<sub>0-t</sub></b> (h*µg/dL) | 787.341±325.544      | 690.000±243.209        |
| <b>t<sub>max</sub></b> (h)         | 5 (3-8)              | 5 (2-8)                |

*Values are arithmetic means ± SD, except for t<sub>max</sub>: median (min-max). N=11*

Descriptive statistics of baseline-corrected iron pharmacokinetic parameters are presented in the table below:

| Pharmacokinetic parameters         | Day 1<br>Single dose | Day 3<br>Multiple dose |
|------------------------------------|----------------------|------------------------|
| <b>C<sub>max</sub></b> (µg/dL)     | 55.445±37.509        | 39.918±27.922          |
| <b>AUC<sub>0-t</sub></b> (h*µg/dL) | 315.995±215.201      | 227.218±182.740        |
| <b>t<sub>max</sub></b> (h)         | 5 (3-8)              | 5 (2-8)                |

*Values are arithmetic means ± SD, except for t<sub>max</sub>: median (min-max). N=11*

## Secondary outcome

Results of the subjective evaluation of the investigational product intake and participant's satisfaction are shown in the table below (N=12):

| Question                                                     | Answer                              | n (%)    |           |           |
|--------------------------------------------------------------|-------------------------------------|----------|-----------|-----------|
|                                                              |                                     | Day 1    | Day 2     | Day 3     |
| How do you rate the ease of swallowing of the product?       | Very easy                           | 8 (66.7) | 11 (91.7) | 10 (83.3) |
|                                                              | Easy                                | 4 (33.3) | 1 (8.3)   | 2 (16.7)  |
|                                                              | Neither easy nor uneasy             | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
|                                                              | Uneasy                              | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
|                                                              | Very uneasy                         | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
| Did you feel a metallic aftertaste after the product intake? | Yes                                 | 6 (50.0) | 2 (16.7)  | 2 (16.7)  |
|                                                              | No                                  | 6 (50.0) | 10 (83.3) | 10 (83.3) |
| If YES, how do you rate this aftertaste?                     | Not applicable                      | 6 (50.0) | 10 (83.3) | 10 (83.3) |
|                                                              | Very mild                           | 0 (0.0)  | 2 (16.7)  | 0 (0.0)   |
|                                                              | Mild                                | 6 (50.0) | 0 (0.0)   | 2 (16.7)  |
|                                                              | Neither mild nor strong             | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
|                                                              | Strong                              | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
|                                                              | Very strong                         | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
| How do you rate your satisfaction with the product?          | Very satisfying                     | 5 (41.7) | 7 (58.3)  | 7 (58.3)  |
|                                                              | Satisfying                          | 5 (41.7) | 3 (25.0)  | 5 (41.7)  |
|                                                              | Neither satisfying nor unsatisfying | 2 (16.7) | 2 (16.7)  | 0 (0.0)   |
|                                                              | Unsatisfying                        | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
|                                                              | Very unsatisfying                   | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
| Would you repeat the use of this product in the future?      | Certainly yes                       | 8 (66.7) | 8 (66.7)  | 8 (66.7)  |
|                                                              | Probably yes                        | 3 (25.0) | 4 (33.3)  | 3 (25.0)  |
|                                                              | Neither yes nor no                  | 1 (8.3)  | 0 (0.0)   | 1 (8.3)   |
|                                                              | Probably no                         | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |
|                                                              | Certainly no                        | 0 (0.0)  | 0 (0.0)   | 0 (0.0)   |

Results of the gastrointestinal tolerability are shown in the table below (N=12):

| Question             | Answer       | n (%)     |          |          |
|----------------------|--------------|-----------|----------|----------|
|                      |              | Day 1     | Day 2    | Day 3    |
| Heartburn            | 0 – None     | 12 (100)  | 12 (100) | 12 (100) |
|                      | 1 - Mild     | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 2 - Moderate | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 3 - Severe   | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
| Stomach discomfort   | 0 – None     | 12 (100)  | 12 (100) | 12 (100) |
|                      | 1 - Mild     | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 2 - Moderate | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 3 - Severe   | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
| Stomach pain         | 0 – None     | 12 (100)  | 12 (100) | 12 (100) |
|                      | 1 - Mild     | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 2 - Moderate | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 3 - Severe   | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
| Abdominal discomfort | 0 – None     | 12 (100)  | 12 (100) | 12 (100) |
|                      | 1 - Mild     | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 2 - Moderate | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 3 - Severe   | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
| Abdominal pain       | 0 – None     | 12 (100)  | 12 (100) | 12 (100) |
|                      | 1 - Mild     | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 2 - Moderate | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 3 - Severe   | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
| Nausea               | 0 – None     | 12 (100)  | 12 (100) | 12 (100) |
|                      | 1 - Mild     | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 2 - Moderate | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 3 - Severe   | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
| Vomiting             | 0 – None     | 11 (91.7) | 12 (100) | 12 (100) |
|                      | 1 - Mild     | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |
|                      | 2 - Moderate | 1 (8.3)   | 0 (0.0)  | 0 (0.0)  |
|                      | 3 - Severe   | 0 (0.0)   | 0 (0.0)  | 0 (0.0)  |

## Adverse events

The number of treatment-emergent adverse events (TEAEs) and the number of participants with TEAEs are shown in the table below:

| Category                   | Overall<br>N=12 |                    |
|----------------------------|-----------------|--------------------|
|                            | n AEs           | n (%) participants |
| All TEAEs                  | 1               | 1 (8.3)            |
| Related                    | 1               | 1 (8.3)            |
| Not related                | 0               | 0 (0.0)            |
| Leading to discontinuation | 0               | 0 (0.0)            |
| SAEs                       | 0               | 0 (0.0)            |

The number of TEAEs and the number and percentage of participants with TEAEs by treatment, system organ class (SOC) and preferred term (PT) are shown in the table below:

| SOC                        | Overall<br>N=12 |                    |
|----------------------------|-----------------|--------------------|
| PT                         | n AEs           | n (%) participants |
| All TEAEs – all SOCs       | 1               | 1 (8.3)            |
| Gastrointestinal disorders | 1               | 1 (8.3)            |
| Vomiting                   | 1               | 1 (8.3)            |

Based on the safety results, the investigational product was generally well tolerated.